Detection of amyloid-beta peptides in the cerebrospinal fluid of patients has been used as a tool to diagnose and follow the development of Alzheimer's disease. However, the efficacy of the existing tools is limited and the capabilities to detect low concentrations and different amyloid-beta peptides are not well developed. Here, a new approach is developed to concentrate the samples and achieve sensitive and simultaneous detection of different amyloid-beta peptides to be used as biomarkers for diagnostic purposes. This electrokinetic system was able to detect subnanomolar ranges of amyloid-beta 38, 40 and 42 in the cerebrospinal fluid of Alzheimer's patients and non-demented controls. The quantification limits of this system coupled to a laser-induced fluorescence detection were 0.05nM, which represents up to 170 times more sensitivity. The researchers present a new tool that can have a great clinical potential to improve the detection of amyloid-beta peptides at very low concentrations, making it easy to track the onset of the disease, without the need of using immune techniques or other complicated approaches.
Online preconcentration in capillaries by multiple large-volume sample stacking: An alternative to immunoassays for quantification of amyloid beta peptides biomarkers in cerebrospinal fluid
The IE from MS no longer understands current scripting languages, the latest main version (version 11) is from 2013 and has not been further developed since 2015.
Our recommendation: Use only the latest versions of modern browsers, for example Google Chrome, Mozilla Firefox or Microsofrt Edge, because only this guarantees you sufficient protection against infections and the correct display of websites!